Carisma Therapeutics Inc. (ticker: CARM) is an OTC-listed pharmaceutical preparations company. DredgeCap's structured extraction of CARM's SEC filings surfaces 4 active risk signals, including 2 delisting/deregistration signals, 1 auditor-change signal, and 1 late-filing signal. CARM reported $49.00M in revenue and $25.68M for the period ending 2025-09-30, with operating cash flow of -$14.06M. Cash and equivalents stood at $2.78M (down 89.7% year-over-year). Total assets of $6.55M are exceeded by total liabilities of $7.42M. Each signal on this page is sourced verbatim from the underlying SEC filing. Use the tabs above to drill into auditor history, going-concern citations, dilution mechanics, cash runway, and the full risk-flag inventory.
CARM SEC Filings
Full cached SEC EDGAR filing history for CARM, grouped by form type and sorted newest-first within each group. 0 filings across 0 form types.
Filings sourced verbatim from SEC EDGAR submissions metadata. “Structured” links route to DredgeCap's per-filing renderer (XBRL-backed financials + cited highlights) when available; the EDGAR link always points to the canonical accession index on sec.gov.